# Kineta Inc. (KA)

Source: https://www.quantisnow.com/company/KA
Generated: 2026-11-09T15:53:52.960Z

- Ticker: KA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2016

## Latest KA news and filings

- 2024-10-08 13:00 UTC [Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors](https://www.quantisnow.com/insight/kineta-announces-completion-of-enrollment-in-the-monotherapy-arm-of-5719321)
- 2024-10-04 13:05 UTC [Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024](https://www.quantisnow.com/insight/kineta-announces-kva12123-abstract-accepted-for-poster-presentation-at-society-5716628)
- 2024-10-02 20:07 UTC [SEC Form 8-K] [Kineta Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kineta-inc-filed-sec-form-8-k-other-events-financial-statements-5712603)
- 2024-10-02 20:05 UTC [Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1](https://www.quantisnow.com/insight/kineta-announces-the-extension-of-the-tuhura-biosciences-exclusivity-and-5712509)
- 2024-09-20 01:53 UTC [SEC Form 8-K] [Kineta Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kineta-inc-filed-sec-form-8-k-other-events-financial-statements-5700247)
- 2024-09-19 22:23 UTC [Kineta, Inc Transitioning from Nasdaq to OTC Markets](https://www.quantisnow.com/insight/kineta-inc-transitioning-from-nasdaq-to-otc-markets-5700140)
- 2024-09-19 13:21 UTC [SEC Form 8-K] [Kineta Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/kineta-inc-filed-sec-form-8-k-notice-of-delisting-or-5699298)
- 2024-09-13 21:20 UTC [SEC Form 8-K] [Kineta Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/kineta-inc-filed-sec-form-8-k-entry-into-a-material-5693836)
- 2024-09-05 20:20 UTC [SEC Form 4] [SEC Form 4 filed by Director Foote Marion R](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-foote-marion-r-5684438)
- 2024-09-05 20:21 UTC [SEC Form 4] [SEC Form 4 filed by Director Iadonato Shawn](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-iadonato-shawn-5684434)
- 2024-09-05 20:21 UTC [SEC Form 4] [SEC Form 4 filed by Director Peters Richard](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-peters-richard-5684429)
- 2024-09-05 20:19 UTC [SEC Form 4] [SEC Form 4 filed by Director Drapkin Kimberlee C](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-drapkin-kimberlee-c-5684426)
- 2024-09-05 20:20 UTC [SEC Form 4] [SEC Form 4 filed by Director Dylla Scott J.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-dylla-scott-j-5684422)
- 2024-09-05 20:19 UTC [SEC Form 4] [SEC Form 4 filed by Director Bartoszek Raymond J.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-bartoszek-raymond-j-5684411)
- 2024-09-05 20:18 UTC [SEC Form 4] [SEC Form 4 filed by Director Arkowitz David](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-arkowitz-david-5684408)
- 2024-08-19 13:01 UTC [SEC Form 8-K] [Kineta Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kineta-inc-filed-sec-form-8-k-other-events-financial-statements-5663946)
- 2024-08-19 13:00 UTC [TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer](https://www.quantisnow.com/insight/tuhura-biosciences-and-kintara-therapeutics-announce-kineta-inc-reopens-enrollment-5663934)
- 2024-08-19 13:00 UTC [Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer](https://www.quantisnow.com/insight/kineta-reopens-enrollment-for-the-vista-101-clinical-trial-evaluating-kva12123-5663914)
- 2024-08-08 20:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Kineta Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-kineta-inc-5650165)
- 2024-07-08 11:34 UTC [Market Chatter] [Kineta shares are trading higher after the company announced that it entered into an exclusivity and right of first offer agreement with TuHURA Biosciences to grant the immune-oncology company exclusive rights to acquire its Anti-VISTA antibody.](https://www.quantisnow.com/insight/kineta-shares-are-trading-higher-after-the-company-announced-that-5596188)
- 2024-07-08 10:35 UTC [Market Chatter] [TuHURA Biosciences And Kintara Therapeutics Announce Agreement For Potential Acquisition Of Kineta's Anti-VISTA Antibody](https://www.quantisnow.com/insight/tuhura-biosciences-and-kintara-therapeutics-announce-agreement-for-potential-acquisition-5596016)
- 2024-07-08 10:30 UTC [SEC Form 8-K] [Kineta Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kineta-inc-filed-sec-form-8-k-entry-into-a-material-5596013)
- 2024-07-08 10:30 UTC [TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor](https://www.quantisnow.com/insight/tuhura-biosciences-enters-into-exclusivity-and-right-of-first-offer-5596011)
- 2024-07-08 10:30 UTC [Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences](https://www.quantisnow.com/insight/kineta-announces-exclusivity-and-right-of-first-offer-agreement-for-5596007)
- 2024-06-25 20:00 UTC [SEC Form 8-K] [Kineta Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/kineta-inc-filed-sec-form-8-k-submission-of-matters-to-5576280)
- 2024-06-20 20:31 UTC [Market Insight] [12 Health Care Stocks Moving In Thursday's After-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-thursdays-after-market-session-5568960)
- 2024-06-17 12:43 UTC [Market Insight] [Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket](https://www.quantisnow.com/insight/why-nurix-therapeutics-shares-are-trading-higher-by-around-12-5561026)
- 2024-06-17 12:07 UTC [Market Insight] [12 Health Care Stocks Moving In Monday's Pre-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-mondays-pre-market-session-5560891)
- 2024-06-14 20:31 UTC [Market Insight] [12 Health Care Stocks Moving In Friday's After-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-fridays-after-market-session-5559481)
- 2024-06-06 16:31 UTC [Market Insight] [12 Health Care Stocks Moving In Thursday's Intraday Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-thursdays-intraday-session-5541949)
- 2024-06-05 16:31 UTC [Market Insight] [12 Health Care Stocks Moving In Wednesday's Intraday Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-wednesdays-intraday-session-5538927)
- 2024-05-30 20:00 UTC [SEC Form 8-K] [Kineta Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/kineta-inc-filed-sec-form-8-k-notice-of-delisting-or-5526153)
- 2024-05-29 12:06 UTC [Market Insight] [12 Health Care Stocks Moving In Wednesday's Pre-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-wednesdays-pre-market-session-5521970)
- 2024-05-15 20:21 UTC [Market Chatter] [Kineta Provides Update On Its Ongoing Phase 1/2 VISTA-101 Clinical Trial And Corporate Activities; Received $500,000 Investment From An Existing Investor](https://www.quantisnow.com/insight/kineta-provides-update-on-its-ongoing-phase-12-vista-101-clinical-5493586)
- 2024-05-15 20:20 UTC [Market Chatter] [Kineta Q1 EPS $(0.89) Misses $(0.21) Estimate](https://www.quantisnow.com/insight/kineta-q1-eps-089-misses-021-estimate-5493569)
- 2024-05-15 20:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Kineta Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-kineta-inc-5493263)
- 2024-05-15 20:03 UTC [SEC Form 8-K] [Kineta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kineta-inc-filed-sec-form-8-k-results-of-operations-and-5493123)
- 2024-05-15 20:02 UTC [Market Chatter] [Kineta Says Actively Exploring Strategic Alternatives To Maximize Value For All Stakeholders](https://www.quantisnow.com/insight/kineta-says-actively-exploring-strategic-alternatives-to-maximize-value-for-5493006)
- 2024-05-15 20:01 UTC [Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities](https://www.quantisnow.com/insight/kineta-reports-first-quarter-2024-financial-results-and-provides-update-5492972)
- 2024-05-02 20:39 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Kineta Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-kineta-inc-amendment-5455230)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/KA
- Earnings history: https://www.quantisnow.com/earnings/KA
- Dividend history: https://www.quantisnow.com/dividends/KA
- Insider transactions: https://www.quantisnow.com/insiders/KA
- Options chain: https://www.quantisnow.com/options/KA
- SEC 8-K filings only: https://www.quantisnow.com/company/KA/8-k
- RSS and alerts for KA: https://www.quantisnow.com/docs/rss-feeds.md